Imaging Characteristics of Coexisting Metastatic Papillary Thyroid Cancer and Prostate Cancer on 18F-Fluciclovine and 68Ga-PSMA-11 PET/CT

被引:3
|
作者
Lu, Yang [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Nucl Med, Div Diagnost Imaging, 1400 Pressler St,Unit 1483, Houston, TX 77030 USA
关键词
Ga-68-PSMA-11; PET; F-18-fluciclovine PET; thyroid cancer; prostate cancer; metastasis; TRANSPORT; ACID; EXPRESSION;
D O I
10.1097/RLU.0000000000004156
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
A 76-year-old man with biopsy-proven metastatic papillary thyroid cancer in a mediastinal nodule status post total thyroidectomy is on surveillance. The patient also had prostate cancer and received prostatectomy and androgen deprivation treatment. An F-18-fluciclovine PET revealed avid lesions in the mediastinal nodule and a sclerotic focus at L5 with concurrent prostate-specific antigen level of 0.4 ng/mL. The L5 lesion was later biopsied and confirmed as metastasis from prostate cancer. A Ga-68-PSMA-11 PET 2 months later showed avid radiotracer uptake within L5 metastasis but not the mediastinal nodule. The patient received radiation therapy to the L5 lesion and responded well.
引用
收藏
页码:820 / 821
页数:2
相关论文
共 50 条
  • [41] Cavernosal Metastasis From Prostate Cancer on 18F-Fluciclovine PET/CT
    Nguyen, Ba D.
    CLINICAL NUCLEAR MEDICINE, 2020, 45 (10) : E449 - E450
  • [42] The additional value of 18F-FDG PET/CT compared to 68Ga-PSMA-11 PET/CT in initial diagnosed prostate cancer patients
    Wang, Yining
    Liu, Jianjun
    Chen, Ruohua
    JOURNAL OF NUCLEAR MEDICINE, 2021, 62
  • [43] 68Ga-PSMA-11 and 18F-FDG PET/CT in a Case of Ductal Adenocarcinoma of the Prostate
    Qiu, Shuang
    Dong, Aisheng
    Zhu, Yan
    Zuo, Changjing
    CLINICAL NUCLEAR MEDICINE, 2022, 47 (09) : 836 - 838
  • [44] 68Ga-PSMA-11 PET Angiogenesis Imaging In Metastatic Clear Cell Renal Cancer: Can It Replace 18F-FDG PET?
    Singh, H.
    Aggarwal, P.
    Das, C. K.
    Mavuduru, R.
    Kakkar, N.
    Kumar, R.
    Mittal, B.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S193 - S193
  • [45] A PROSPECTIVE INTRA-INDIVIDUAL BLINDED COMPARISON OF 18F-PSMA-1007 AND 68GA-PSMA-11 PET/CT IMAGING IN PATIENTS WITH CONFIRMED PROSTATE CANCER
    Debowski, M.
    Gulhane, B.
    Ramsay, S. C.
    Thomas, P. A.
    Garcia, P.
    Latter, M.
    Tapper, S.
    Pattison, D. A.
    INTERNAL MEDICINE JOURNAL, 2019, 49 : 27 - 27
  • [46] The value of 68Ga-PSMA-11 PET/CT in patients with prostate cancer and inconclusive standard imaging at primary staging
    Nalliah, Surenth
    Zacho, Helle D.
    NUCLEAR MEDICINE COMMUNICATIONS, 2022, 43 (10) : 1092 - 1098
  • [47] 68Ga-PSMA-11 PET/CT versus 68Ga-PSMA-11 PET/MRI for the detection of biochemically recurrent prostate cancer: a systematic review and meta-analysis
    Huang, Ruizhe
    Li, Yizhen
    Wu, Haowen
    Liu, Boyi
    Zhang, Xuanjun
    Zhang, Zhongxi
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [48] Optimal Time Point for 68Ga-PSMA-11 PET/CT Imaging in the Assessment of Suspected Metastatic Prostate Cancer in the Bladder of Postprostatectomy Patient
    Xu, Guofan
    Lu, Yang
    CLINICAL NUCLEAR MEDICINE, 2021, 46 (08) : 675 - 676
  • [49] The "Ultimate Triple PET" 68Ga-DOTATATE, 18F-FDG, and 18F-Fluciclovine PET/CT Findings in a Single Patient With Metastatic Abdominal Carcinoid and Prostate Cancer
    McClenathan, Matthew
    Peacock, Justin G.
    CLINICAL NUCLEAR MEDICINE, 2022, 47 (02) : E161 - E164
  • [50] "Seeing Is Believing": Additive Utility of 68Ga-PSMA-11 PET/CT in Prostate Cancer Diagnosis
    Chin, Joel
    Tan, Yu Guang
    Lee, Alvin
    Ng, Tze Kiat
    Shi, Ruoyu
    Tang, Charlene Yu Lin
    Thang, Sue Ping
    Tuan, Jeffrey Kit Loong
    Cheng, Christopher Wai Sam
    Tay, Kae Jack
    Ho, Henry Sun Sien
    Wang, Hung-Jen
    Chiu, Peter Ka-Fung
    Teoh, Jeremy Yuen-Chun
    Lam, Winnie Wing-Chuen
    Law, Yan Mee
    Yuen, John Shyi Peng
    Chen, Kenneth
    CANCERS, 2024, 16 (09)